Takahashi Satoshi, Yoshida Kazunari, Kawase Takeshi
Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan.
Keio J Med. 2011;60(2):56-64. doi: 10.2302/kjm.60.56.
In this report, we review 41 patients with intracranial germ cell tumors (GCTs) treated at the Department of Neurosurgery, Keio University School of Medicine, in the 25-year period between January 1982 and July 2006. The main aim of the present study was to compare the effectiveness of our current intracranial GCT management protocol, comprising neoadjuvant chemo-radiotherapy without surgical biopsy of tumors as far as possible, to that of historical controls. In all patients, charts were reviewed and tumor and patient characteristics, including age, sex, type of tumor marker secreted, treatment protocol, and clinical outcomes, were compared. The relationship between these variables was analyzed by means of the Cox proportional hazards model. Thus far, four patients treated by approaches other than the current protocol have died of their tumor. The overall 5-, 10-, and 15-year survival rates of all the patients calculated by the Kaplan-Meier method were 91.9%, 88.6%, and 88.6%, respectively. According to the results of the Cox proportional hazards model, patients with secreting GCTs show statistically poorer prognoses than those with non-secreting GCTs (P = 0.0073), and although not statistically significant, patients treated with our current protocol tend to show better prognoses than historical controls (P = 0.0543). All five patients with secreting GCT treated using our current protocol are still alive after an average follow-up period exceeding 7 years, and only one of these has shown tumor recurrence. With our current treatment protocol comprising neoadjuvant chemo-radiotherapy without surgical biopsy, prognoses of patients with GCTs have improved compared to historical controls at our institution.
在本报告中,我们回顾了1982年1月至2006年7月这25年间在庆应义塾大学医学院神经外科接受治疗的41例颅内生殖细胞肿瘤(GCT)患者。本研究的主要目的是将我们目前的颅内GCT管理方案(尽可能在不进行肿瘤手术活检的情况下进行新辅助放化疗)的有效性与历史对照进行比较。对所有患者的病历进行了回顾,并比较了肿瘤和患者的特征,包括年龄、性别、分泌的肿瘤标志物类型、治疗方案和临床结果。通过Cox比例风险模型分析这些变量之间的关系。到目前为止,4例采用当前方案以外的方法治疗的患者已死于肿瘤。采用Kaplan-Meier方法计算的所有患者的5年、10年和15年总生存率分别为91.9%、88.6%和88.6%。根据Cox比例风险模型的结果,分泌型GCT患者的预后在统计学上比非分泌型GCT患者差(P = 0.0073),并且尽管无统计学意义,但采用我们当前方案治疗的患者的预后往往比历史对照更好(P = 0.0543)。采用我们当前方案治疗的所有5例分泌型GCT患者在平均随访期超过7年后仍然存活,其中只有1例出现肿瘤复发。通过我们目前包括新辅助放化疗且不进行手术活检的治疗方案,GCT患者的预后与我们机构的历史对照相比有所改善。